Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
PRECISION BIOSCIENCES INC (DTIL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2023 4 Kelly John Alexander (CFO) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 90,000 shares @ $0.48, valued at $43.2k
08/21/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. ASSET PURCHASE AGREEMENT BY AND AMONG PRECISION BIOSCIENCES, INC., IMUGENE INC. and IMUGENE LIMITED August 15, 2023",
"Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and between IMUGENE INC. and PRECISION BIOSCIENCES, INC. LICENSE AGREEMENT This License Agreement is entered into as of August 15, 2023 , by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, U.S.A. , and Imugene Inc., a corporation organized and existing under the laws of Nevada, with its principal business office located at Suite 200, 701 South Carson St, Carson City, Nevada 89701, U.S.A. . Imugene and Precision are each hereafter referred to individually...",
"Precision BioSciences, Inc. Unaudited Pro Forma Condensed Consolidated Financial Statements On August 15, 2023, Precision BioSciences, Inc. entered into an Asset Purchase Agreement with Imugene Limited, an Australian corporation , and its wholly owned subsidiary Imugene Inc. , a Nevada corporation . Pursuant to and simultaneously with the execution of the Purchase Agreement, on August 15, 2023 , Imugene US acquired the manufacturing infrastructure to the Company’s CAR T program that uses azer-cel for the potential treatment of relapsed or refractory non-Hodgkin lymphoma, which includes the Company’s MCAT facility, certain contracts of the Company with respect to the MCAT facility and the Company’s azer-cel program, including the lease to the MCAT facility, and related equipment, supplies, ..."
08/04/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update - FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions Ongoing - Presented Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy and Chronic Hepatitis B - Company plans to host In Vivo Gene Editing R&D Day on September 12, 2023 - Cash Balance Provides Expected Runway Through Q1 2025"
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/06/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. EXECUTION VERSION amended and restated DEVELOPMENT AND LICENSE AGREEMENT between PREVAIL THERAPEUTICS INC. and PRECISION BIOSCIENCES, INC. AMENDED AND RESTATED Development AND LICENSE AGREEMENT This Amended and Restated Development and License Agreement entered into as of June 30, 2023 , by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, U.S.A. , and Prevail Therapeutics Inc., a corporation organized and existing under the laws of Delaware, with its principal business office..."
06/16/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/09/2023 4 Barton Shane (VP & Corporate Controller) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Exercised 6,060 restricted stock units @ $0
06/09/2023 4 Kelly John Alexander (CFO) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Exercised 34,091 restricted stock units @ $0
Exercised 13,635 restricted stock units @ $0
06/09/2023 4 SMITH J. JEFFERSON (Chief Research Officer) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Exercised 4,872 restricted stock units @ $0
06/09/2023 4 Scimeca Dario (General Counsel and Secretary) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Sold 13,361 shares @ $0.75, valued at $10k
Exercised 22,727 restricted stock units @ $0
Exercised 9,044 restricted stock units @ $0
06/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
05/31/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T Related Adverse Events Were Observed Azer-Cel Achieved 83% Overall Response Rate , 61% Complete Response Rate with 55% Durable Response Greater Than or Equal to Six Months Among Evaluable CAR T Relapsed Subjects Upcoming Azer-Cel Meeting with FDA in June to Align on Potential Phase 2 Study in CAR T Relapsed Diffuse Large B-cell Lymphoma ; Focus on Trial Design, Size, and Endpoints PBCAR19B Stealth Cell Proof of Concept Achieved; Designed to Enable Expansion and Persistence by Delaying Host Rejection Throug..."
05/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update - Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT Conference - In Vivo Gene Editing R&D Day Planned for Mid-2023 - Cash Balance Provides Expected Runway through Q1 2025"
05/08/2023 4 Frankel Stanley (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 126,075 restricted stock units @ $0
05/08/2023 4 Buehler Kevin (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 126,075 restricted stock units @ $0
05/08/2023 4 Wadsworth Samuel C. (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 126,075 restricted stock units @ $0
05/08/2023 4 Pire Shari Lisa (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 126,075 restricted stock units @ $0
05/08/2023 4 Brown Melinda (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 126,075 restricted stock units @ $0
05/08/2023 4 Germano Geno J (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Granted 126,075 restricted stock units @ $0
04/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/28/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
04/27/2023 144 Form 144 - Report of proposed sale of securities:
04/18/2023 8-K Quarterly results
04/13/2023 4 Buehler Kevin (Director) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Exercised 5,701 restricted stock units @ $0
03/23/2023 ARS Form ARS - Annual Report to Security Holders:
03/23/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/23/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/23/2023 4 Amoroso Michael (President and CEO) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Sold 46,999 shares @ $0.82, valued at $38.5k
Exercised 102,535 restricted stock units @ $0
03/21/2023 4 Kelly John Alexander (CFO) has filed a Form 4 on PRECISION BIOSCIENCES INC
Txns: Bought 20,000 shares @ $0.86, valued at $17.2k
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update - Advanced ARCUS Gene Editing Development for Clinical and Research Programs; In Vivo Gene Editing R&D Day Planned for Mid-2023 - Progressed Azer-cel and PBCAR19B Allogenic CAR T Clinical Studies; Program Updates Planned for Azer-cel and PBCAR19B - Advanced Wholly Owned, Preclinical PBGENE-HBV and Partnered DMD, Sickle Cell Disease, and OTC Programs; New Data Expected to be Presented/Published in 2023 - Cash Balance Provides Expected 2-Year Runway through Q1 2025"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy